Stock Buyback Is Vote Of Confidence From Genmab Board

 
• By Kevin Grogan

The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares

Genmab Office Copenhagen - close up
The Danish Biotech Has Growth In Its Sights • Source: Genmab

More from Strategy

More from Therapy Areas